Insider Transactions in Q1 2024 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2024
|
Todd C Davis Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,015
+3.35%
|
$992,930
$62.04 P/Share
|
|
Mar 05
2024
|
Stephen L Sabba Director |
SELL
Open market or private sale
|
Direct |
1,893
-6.14%
|
$140,082
$74.3 P/Share
|
|
Mar 05
2024
|
Stephen L Sabba Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,893
+8.58%
|
-
|
|
Mar 05
2024
|
Jason Aryeh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,893
+3.74%
|
$112,827
$39.35 P/Share
|
|
Feb 28
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
140
-0.47%
|
$12,320
$88.46 P/Share
|
|
Feb 28
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,264
+1.4%
|
$72,048
$57.15 P/Share
|
|
Feb 27
2024
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,436
+23.75%
|
-
|
|
Feb 27
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,208
+20.11%
|
-
|
|
Feb 27
2024
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,416
+12.19%
|
-
|
|
Feb 27
2024
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,208
+24.51%
|
-
|
|
Feb 15
2024
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,381
-1.89%
|
$102,194
$74.65 P/Share
|
|
Feb 15
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,479
-6.46%
|
$109,446
$74.65 P/Share
|
|
Feb 15
2024
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,778
-5.07%
|
$353,572
$74.65 P/Share
|
|
Feb 15
2024
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
593
-3.8%
|
$43,882
$74.65 P/Share
|
|
Jan 02
2024
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,917
-3.0%
|
$210,024
$72.31 P/Share
|